Gene therapy for sickle cell disease passes key preclinical test — Harvard Gazette

A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red-cell damage in mice with sickle cell disease, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported in the Journal of Clinical Investigation.

World-first gene therapy for 2 blood disorders — sickle cell and thalassemia — approved

Health Archives — Page 34 of 107 — Harvard Gazette

Gene therapy for sickle cell disease: moving from the bench to the bedside - ScienceDirect

PDF) Editing Human DNA Moral and social implications of germline genetic modification

gene therapy, The Stem Cellar

Gene therapy for sickle cell disease passes key preclinical test — Harvard Gazette

SEC Filing CRISPR Therapeutics

CRISPR Sickle Cell Gene Therapy: Approaches, Challenges, and Progress

Gene therapy for sickle cell disease passes key preclinical test — Harvard Gazette

SEC Filing CRISPR Therapeutics

New study shows promising evidence for sickle cell gene therapy - UChicago Medicine